Article
mTORC1 activity is essential for disease progression in chronic lymphocytic leukemia
medRxiv · 2022 · Malik, N.; Hay, J.; Dunn, K. M.; Nakagawa, R.; Sansom, O. J.; Michie, A. M.
Key facts
| Title | mTORC1 activity is essential for disease progression in chronic lymphocytic leukemia |
|---|---|
| First author | Malik, N.; Hay, J.; Dunn, K. M.; Nakagawa, R.; Sansom, O. J.; Michie, A. M. |
| Journal | medRxiv |
| Published | Apr 20, 2022 |
| DOI | 10.1101/2022.04.19.488778 |
| Devices mentioned | K852441, K854177, K854178, K854179, K854180, K854181, K854182, K854183, K854184, K854185, K854186, K854187 and 1 more |
| Product codes mentioned | CDT, CEO, CGA, CGX, CHH, CIG, CIS, CIX, CJE, CKA, KLB, KLS and 3 more |
At a glance
- 10–99 FDA submissions mentioned
- 10–99 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1